Tan 2002

Methods	Country: China Setting/Design: Hospital Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 6 months Loss to follow‐up: 0
Participants	Inclusion criteria DM: Type 2 HbA1c: < 10% Mean AER: 20‐200 µg/min BP: Sitting ≤ 140/89 mm Hg Controlled hypertension with no changes in antihypertensive therapy in the preceding 3 months Losartan group Number: 40 Age: 54.7 (10.1) Sex (M/F): 22/18 Placebo group Number: 40 Age: 54.3 (8.8) Sex (M/F): 18/22 Exclusion criteria Treatment with ACEi Major CVE
Interventions	Losartan group 50 mg/d Placebo group Co‐interventions: No
Outcomes	Endothelium function Mean AER BP CrCl
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear